drugset
drugset / Trial / NCT07773246

Phase 1/2 Study of KRRO-121 in Healthy Volunteers and Patients With UCD

NCT07773246 ↗

Phase 1/2 Recruiting 30 enrolled Korro Bio, Inc.
RandomizedSequentialTriple-blindTreatment

Summary

Phase 1/2 Study of KRRO-121 is a randomized, placebo-controlled study in Healthy Volunteers (Phase 1 SAD and MAD) and Study Participants with Urea Cycle Disorders (Phase 2). The primary objective of the study is to evaluate the safety of KRRO-121.

Timeline

Start
2026-09-28
Primary completion
2027-08
Completion
2027-09

Drugs

EvaluationDrugModalityDoseRoute
Subject KRRO-121 Oligonucleotide (other) — Subcutaneous

Indications

arginase deficiency argininosuccinic aciduria carbamoyl phosphate synthetase I deficiency disease citrin deficiency hyperammonemia due to N-acetylglutamate synthase deficiency ornithine carbamoyltransferase deficiency ornithine translocase deficiency